Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Cash from Operations (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Cash from Operations for 16 consecutive years, with 1280813.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 40.62% to 1280813.0 in Q4 2025 year-over-year; TTM through Nov 2025 was 5478606.0, a 8.86% decrease, with the full-year FY2025 number at 5478606.0, down 8.86% from a year prior.
  • Cash from Operations was 1280813.0 for Q4 2025 at Cryo Cell International, down from 2536716.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3344314.0 in Q4 2023 to a low of 356865.0 in Q1 2024.
  • A 5-year average of 1845400.55 and a median of 1944812.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 121.71% in 2024, then surged 367.35% in 2025.
  • Cryo Cell International's Cash from Operations stood at 1667475.0 in 2021, then skyrocketed by 45.71% to 2429736.0 in 2022, then surged by 37.64% to 3344314.0 in 2023, then plummeted by 35.5% to 2156993.0 in 2024, then plummeted by 40.62% to 1280813.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Cash from Operations are 1280813.0 (Q4 2025), 2536716.0 (Q3 2025), and 707014.0 (Q2 2025).